REG - GSK PLC - Director/PDMR Shareholding
13/02/2024 15:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240213:nRSM0174Da&default-theme=true
RNS Number : 0174D GSK PLC 13 February 2024
GSK plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares
and American Depositary Shares ('ADSs') made to Persons Discharging Managerial
Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in
February 2021 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'),
which were subject to relevant business performance conditions, and the
subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards
were made in 2021 and the three-year performance period commenced on 1 January
2021 and ended on 31 December 2023. The vested shares for the Executive
Directors are now subject to an additional two-year vesting period.
The performance measure vesting details for those PDMRs who received awards in
2021 are set out in the following table.
Outcome and Vesting Level
Portion of the Award Measure and Outcome % of maximum % of award
30% Adjusted Free Cash Flow - For the three years ending 31 December 2023, the 100 30.00
Company achieved Adjusted Free Cash Flow calculated in accordance with the
principles for the measure of £9.81bn, which is above the revised amount of
£6.54bn required for maximum vesting.
Adjustments to the original target and vesting schedule were set out in detail
in the 2022 Annual Report.
30% Total Shareholder Return - For the three-year period the Company's Total 0 0.00
Shareholder Return ranked 9th, which is below the threshold vesting level
against a comparator group of 10 global pharmaceutical companies including
GSK.
20% Innovation Sales - For the three-year period, the Company achieved revenues 99.77 19.95
from new products calculated in accordance with the principles for the measure
of £18.651bn, which is slightly below the level of £18.667bn required for
100% vesting. The threshold vesting level was £15.273bn.
20% Pipeline Progress - measure is equally weighted between:
- Pivotal trial starts 100 10.00
- Major regulatory approvals 100 10.00
Total vesting for 2021 award 69.95 69.95
Lapsed 30.05
The notifications that follow are for awards made to PDMRs and their PCAs and
detail the PSP conditional awards that vested, including dividends accrued, on
9 February 2024. The balance of the award made to each PDMR and PCA has
lapsed.
The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting
date were £16.60 and $41.91.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan. These shares are now subject to a
two-year hold.
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 441,309
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 89,414
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 47,864
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 139,077
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 65,367
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 52,746
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 24,791
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dylan Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021, 2022 and 2023
under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 7,642
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dylan Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021, 2022 and 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 3,592
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 195,810
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 13,864
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The number of ADSs vesting on awards granted in 2021 under the Company's 2017
Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 5,383
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADSs to meet tax liabilities for the vesting of awards granted in
2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$41.84 2,894
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 161,385
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 75,851
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 133,024
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 62,522
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 73,728
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 34,653
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, GSK Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 94,120
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, GSK Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 44,237
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 24,473
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 11,503
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The number of Ordinary Shares vesting on awards granted in 2021 under the
Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 9,456
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities for the vesting of awards
granted in 2021 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£16.6055 4,445
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2024-02-09
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFWFIDELSEEERecent news on GSK
See all newsREG - GSK PLC - US FDA accepts new indication filing for Jemperli
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK announces additional EAGLE-1 results
AnnouncementREG - GSK PLC - Results from long-term data relating to Shingrix
Announcement